Translational Utility of Liquid Biopsies in Thyroid Cancer Management

Ayanthi A. Wijewardene; Marthe Chehade; Matti L. Gild; Roderick J. Clifton-Bligh; Martyn Bullock

doi:10.3390/cancers13143443

Cancers (Jul 2021)

Translational Utility of Liquid Biopsies in Thyroid Cancer Management

Ayanthi A. Wijewardene,
Marthe Chehade,
Matti L. Gild,
Roderick J. Clifton-Bligh,
Martyn Bullock

Affiliations

Ayanthi A. Wijewardene: Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW 2052, Australia
Marthe Chehade: Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2052, Australia
Matti L. Gild: Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW 2052, Australia
Roderick J. Clifton-Bligh: Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW 2052, Australia
Martyn Bullock: Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW 2052, Australia

DOI: https://doi.org/10.3390/cancers13143443
Journal volume & issue: Vol. 13, no. 14
p. 3443

Abstract

Read online

Liquid biopsies are a novel technique to assess for either circulating tumor cells (CTC) or circulating tumor DNA (ctDNA and microRNA (miRNA)) in peripheral blood samples of cancer patients. The diagnostic role of liquid biopsy in oncology has expanded in recent years, particularly in lung, colorectal and breast cancer. In thyroid cancer, the role of liquid biopsy in either diagnosis or prognosis is beginning to translate from the lab to the clinic. In this review, we describe the evolution of liquid biopsies in detecting CTC, ctDNA and miRNA in thyroid cancer patients, together with its limitations and future directions in clinical practice.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords